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Poster Session I S251Neutropenia-associated bacteremia has been reported to occur in
20-60% of patients following myeloablative HSCT. Mortality up to
40% may occur with gram negative organisms. To address these
concerns, in 1998 our program revised supportive care guidelines
to include bacterial prophylaxis with meropenem for patients under-
going myeloablative HSCT. Meropenem was started when the
WBC fell below 1000/mcl and continued until the ANC
was$ 500/mcl. This report analyzes outcomes for patients treated
with this strategy.
Between 9/1/1998 and 9/1/2008, 370 transplants were performed.
Of these, 134 who underwent outpatient autologous HSCT received
different infection prophylaxis and were excluded from this analysis.
An additional 24 patients were excluded for other reasons (active bac-
terial infection prior to leukopenia5 15; never received
meropenem5 9). Thus, 212 transplants in 201 patients were evalu-
able for this retrospective analysis (auto5 67 HSCT/65 patients;
allo5 145 HSCT/136 patients). Evaluable patients had a median
of 19 days of ANC\500/mcl (range, 3 – 79 days) between the start
of myeloablation and subsequent myeloid engraftment. The study
group experienced 4409 total days of neutropenic risk for bacteremia.
The outlined strategy was successful in preventing a first bacter-
emic episode in 88% of evaluable transplants (94%, auto; 86%,
allo). Conversely, prophylaxis failed to prevent an initial neutropenic
bacteremia in 12% of transplants (n5 25) overall (6%, auto; 14%,
allo). Meropenem was started at a median of Day -2 (range, Day
-16 to Day +9) and continued for a median of 21 days (range, 1 –
81 days). Initial positive blood cultures occurred at a median of
Day +6 post-HSCT after a median of 10 days of meropenem. Pro-
phylaxis failures were primarily with organisms innately resistant
to meropenem (Coag Negative Staphylococci5 16; Enterococcus5 2;
Stenotrophomonas5 3; other5 4). No instances of meropenem-in-
duced resistant organisms were identified in failures of primary pro-
phylaxis. Initial bacteremias contributed to the deaths of 3 patients,
all post allogeneic HSCT. Thus, neutropenic bacteremias were the
cause of death in 1.4% of all transplants (3/212); none in autologous
HSCT (0/67), 2% in allogeneic HSCT (3/145).
In summary, these results suggest that prophylactic use of merope-
nem may be an effective strategy for reducing the risk of bacteremia
and septic death in children, adolescents and young adults undergo-
ing myeloablative autologous or allogeneic HSCT.250
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Invasive fungal infections (IFI) are a major cause of morbidity and
mortality in allogeneic hematopoietic stem cell transplant (HSCT)
recipients. Galactomannan enzyme immunoassay (EIA) surveillance
testing offers the potential for earlier diagnosis and initiation of ther-
apy. The majority of data regarding galactomannan EIA testing after
HSCT is reported in adult patients. Approval was obtained from the
Institutional Review Board at our institution for a retrospective chart
review of allogeneic HSCT patients from July 1, 2007 July 30, 2009.
Galactomannan EIA testing was obtained 314 times among the 27
patients for an average of 11.6 tests per patient. IFI was defined as ei-
ther proven or probable disease based on the European Organization
for Research and Treatment of Cancer/Mycosis Study Group guide-
lines. Among the 27 patients, there were no cases of proven disease, 1
case of probable disease, and 8 cases of possible disease. There were 5
positive isolated tests without evidence of disease in 4 different pa-
tients. The galactomannan EIA had a sensitivity of 1.00, specificity
of 0.5, positive predictive value (PPV) of 0.07, and negative predic-
tive value (NPV) of 1. Of the 8 patients with possible IFI, 4 had
chronic GVHD. The galactomannan EIA values among the possible
IFI cases ranged from 0.59-7.69. The one probable IFI case also had
chronic GVHD and galactomannan EIA values ranged from 0.5-
1.12. Among the 4 patients with positive tests without evidence of
disease, the galactomannan EIA values ranged from 0.56- 8.57.
None of these patients had identified risk factors for false-positivetests such as administration of beta-lactam antibiotics or gastrointes-
tinal GVHD. Among our patients, the incidence of IFI was 3.7%,
well under the typically reported incidence of 7-10% in allogeneic
HSCT recipients. A decreased incidence and consequently de-
creased prevalence of IFI in our patients likely explains the decreased
PPV but preserved NPV of galactomannan EIA screening in our pe-
diatric allogeneic HSCT patients. HSCT centers should be aware of
the impact of their local incidence of IFI on the performance charac-
teristics of galactomannan EIA.
Table 1. Diagnostic Validity of Galactomannan EIA testing
Positive IFI Negative IFIPositive Galactomannan EIA 1 13
Negative Galactomannan EIA 0 13Sensitivity5 1/15 1.0 Specificity5 13/265 0.5 Positive Predictive Val-
ue5 1/145 0.07 Negative Predictive Value5 13/135 1.0251
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Eosinophilia has been proposed to have prognostic significance
for survival and for the development of graft-versus-host disease
(GVHD) in adult patients following hematopoietic stem cell trans-
plantation (HSCT). However, the prognostic significance of post-
transplant eosinophilia in regards to GVHD and overall survival
has not been well-studied in the pediatric population. We performed
a retrospective analysis of the clinical impact of eosinophilia in 84 pe-
diatric patients following allogeneic HSCT performed for malignant
and non-malignant diseases. The clinical outcomes of patients with
eosinophilia were compared to patients transplanted during the
same time period that did not have eosinophilia. Eosinophilia was
defined as either an absolute number of greater than 0.5  10^9/L
or an eosinophil percentage greater than 4 in the peripheral blood
on at least two consecutive measurements. Seventy-one patients de-
veloped eosinophilia at a median 155 days from transplant. Forty-
two percent of patients had absolute eosinophilia and eighty-three
percent of patients had an elevated eosinophil percentage. The over-
all survival of all patients was sixty-nine percent. Thirty-six percent
of patients developed chronic GVHD and thirty percent developed
acute GVHD. Eosinophilia was not significantly associated with in-
creased mortality (odds ratio 2.7, 95% confidence interval 0.8-8.5);
acute GVHD (OR 2.6, CI 0.5-12.5), or chronic GVHD (OR 2.1,
CI 0.4-10.2). In this pediatric population, post-HSCT eosinophilia
does not have prognostic significance for mortality or the presence
or development of GVHD. Larger pediatric studies are needed to
further evaluate the impact of eosinophilia in children.252
HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH
FANCONI ANEMIA: WHAT ARE THE NUTRITIONAL CONSENQUENCES?
Campos, D.J., Koerich, A., Biagini, G.L., Bonfim, C.M.S., Zanis Neto, J.,
Boguszewski, C.L., Borba, V.Z.C. Federal University of Parana, Curitiba,
PR, Brazil
Introduction: Fanconi Anemia (FA) is a rare disease characterized
by bone marrow failure, congenital abnormalities and a predisposi-
tion to cancer. Patients (pts) with FA usually have low birth weight,
short stature and fatigue. Hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for pts that develop hematological
abnormalities but it increases energy expenditure due to complica-
tions related to this procedure and decreases oral ingestion by the
presence of gastrointestinal symptoms.
Objective: Evaluate the changes in nutritional status, in food intake,
in bone mineral density (BMD) and in vitamin D serum levels in
